CD34 and acute myeloid leukemia: In our cohort of high-risk AML patients, clinical sensitivity for relapse by C-Flow-MRD was substantially from CD34+ aberrancies, however for 8 of 90 analysed pre-relapse samples, MRD was only detectable in the CD34-117+ compartment.